NAD IV therapy is a medical treatment that involves the intravenous administration of nicotinamide adenine dinucleotide (NAD+), a coenzyme that is involved in various cellular processes. The frequency of NAD IV therapy can vary depending on the individual and the specific medical condition being treated. To best answer this for you as an individual, you will need to consult our paramedics and base their consultation on your initial therapy which usually starts at 250 mg.
NAD IV therapy is often used to treat substance abuse, chronic fatigue syndrome, and other conditions. Typically, individuals undergoing NAD IV therapy will receive multiple infusions over a period of days or weeks. The specific dosing and frequency of infusions will depend on the individual's needs and the treatment plan developed by their healthcare provider.
It's important to note that NAD IV therapy is a medical treatment that should only be administered by a licensed healthcare professional in a clinical setting. The decision to undergo NAD IV therapy should be made in consultation with a healthcare provider who can help determine the appropriate frequency and duration of treatment for the individual.
NAD+ IV has become known as the "miracle molecule" due to its anti-aging and rejuvenating effects on the body. NAD is synthesized from vitamin B3, which is niacin, and from amino acids tryptophan and aspartate. The amount of NAD in the body drops as we age, which leads to inflammation, toxins staying in the cell, and cell death. However, using anti-aging protocols, IVs, supplements, exercise, and detoxification can reverse some of the aging that has happened in the body or at least slow down the aging process. NAD has been used since the 1960s for alcohol and drug withdrawals and is being studied for its effects on Parkinson's and Alzheimer's. It reduces stress, depression, and anxiety scores, and it has been used as a detoxification method for patients who have been on long-term antidepressants, anxiolytics, and pain medications.
NAD has been shown to have a rejuvenating effect on the brain cells, helps with mental clarity and focus, and improves sleep. It has also been used to help metabolic issues like obesity, cardiac issues, insulin resistance, and resistance to weight loss, and it helps athletes with their athletic performance. It helps put on a little bit of muscle and lose some of the fat in the body, and it helps with recovery and pain after a workout. NAD has been found to be really effective with patients who have chronic fatigue syndrome or any of the other viral issues like Epstein-Barr virus or Lyme's disease. NAD has antioxidant properties, so it also works as an anti-inflammatory, and it helps with immune system function. NAD has no documented adverse reactions, and very high doses and multiple days in a row have not shown any adverse reactions in the body.
Michael Lickteig, along with his wife Melissa, built Liberty IV Infusion Therapy to serve the North Texas community. Both Michael and Melissa are Nationally Registered Paramedics licensed in the State of Texas, and both hold National Board Certification as Certified Flight Paramedics. Their careers in emergency medicine span more than a decade working in prehospital emergency 911 and critical care transport, as well as on staff inside some of North Texas’ busiest emergency/trauma units serving both adult and pediatric populations.. Michael holds an MBA from the University of North Texas and Melissa a BS degree from the University of Texas Arlington. The Lickteig family has strong ties to the military and has established partnerships with retired veterans and first responder organizations dedicated to reducing the occurrence of suicide in these vulnerable groups. Their goal is to make care available and affordable to veterans, first responders, or anyone else who is struggling with chronic pain, TBI, or PTSD throughout the North Texas Region.
Michael Lickteig NRP , LP, FP-C, MBA
Melissa Lickteig NRP, LP, FP-C, BS
Sobriety and Satiety: Is NAD+ the Answer?
NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis
Clinical Evidence for Targeting NAD Therapeutically